Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.

Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE.

Cancer Res. 2011 May 1;71(9):3175-81. doi: 10.1158/0008-5472.CAN-10-4035. Erratum in: Cancer Res. 2011 Jun 15;71(12):4325.

PMID:
21531763
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.

Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG.

Cancer Immunol Immunother. 2012 Jul;61(7):953-62. doi: 10.1007/s00262-012-1254-0. Epub 2012 Apr 22. Review.

PMID:
22527245
[PubMed - indexed for MEDLINE]
3.

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.

Han EQ, Li XL, Wang CR, Li TF, Han SY.

J Hematol Oncol. 2013 Jul 8;6:47. doi: 10.1186/1756-8722-6-47. Review.

PMID:
23829929
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.

Curran KJ, Pegram HJ, Brentjens RJ.

J Gene Med. 2012 Jun;14(6):405-15. doi: 10.1002/jgm.2604. Review.

PMID:
22262649
[PubMed - indexed for MEDLINE]
5.

Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.

Zhang Q, Li H, Yang J, Li L, Zhang B, Li J, Zheng J.

Curr Gene Ther. 2013 Feb;13(1):65-70. Review.

PMID:
23256743
[PubMed - indexed for MEDLINE]
6.

Treating cancer with genetically engineered T cells.

Park TS, Rosenberg SA, Morgan RA.

Trends Biotechnol. 2011 Nov;29(11):550-7. doi: 10.1016/j.tibtech.2011.04.009. Epub 2011 Jun 12. Review.

PMID:
21663987
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.

Henderson MA, Yong CS, Duong CP, Davenport AJ, John LB, Devaud C, Neeson P, Westwood JA, Darcy PK, Kershaw MH.

Immunotherapy. 2013 Jun;5(6):577-90. doi: 10.2217/imt.13.37.

PMID:
23725282
[PubMed - indexed for MEDLINE]
8.

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

Davies DM, Maher J.

Arch Immunol Ther Exp (Warsz). 2010 Jun;58(3):165-78. doi: 10.1007/s00005-010-0074-1. Epub 2010 Apr 6. Review.

PMID:
20373147
[PubMed - indexed for MEDLINE]
9.

Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.

Shirasu N, Kuroki M.

Anticancer Res. 2012 Jun;32(6):2377-83. Review.

PMID:
22641678
[PubMed - indexed for MEDLINE]
10.

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

Gilham DE, Debets R, Pule M, Hawkins RE, Abken H.

Trends Mol Med. 2012 Jul;18(7):377-84. doi: 10.1016/j.molmed.2012.04.009. Epub 2012 May 19. Review.

PMID:
22613370
[PubMed - indexed for MEDLINE]
11.

CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.

Bridgeman JS, Ladell K, Sheard VE, Miners K, Hawkins RE, Price DA, Gilham DE.

Clin Exp Immunol. 2014 Feb;175(2):258-67. doi: 10.1111/cei.12216.

PMID:
24116999
[PubMed - indexed for MEDLINE]
12.

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Jensen MC, Riddell SR.

Immunol Rev. 2014 Jan;257(1):127-44. doi: 10.1111/imr.12139. Review. Erratum in: Immunol Rev. 2014 Mar;258(1):259.

PMID:
24329794
[PubMed - indexed for MEDLINE]
13.

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Ramos CA, Dotti G.

Expert Opin Biol Ther. 2011 Jul;11(7):855-73. doi: 10.1517/14712598.2011.573476. Epub 2011 Apr 4. Review.

PMID:
21463133
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.

Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.

J Hematol Oncol. 2013 May 9;6:33. doi: 10.1186/1756-8722-6-33.

PMID:
23656794
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.

Hombach AA, Holzinger A, Abken H.

Curr Mol Med. 2013 Aug;13(7):1079-88. Review.

PMID:
23116267
[PubMed - indexed for MEDLINE]
16.

Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.

Hombach A, Pohl C, Reinhold U, Abken H.

Hybridoma. 1999 Feb;18(1):57-61. Review.

PMID:
10211789
[PubMed - indexed for MEDLINE]
17.

The promise and potential pitfalls of chimeric antigen receptors.

Sadelain M, Brentjens R, Rivière I.

Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25. Review.

PMID:
19327974
[PubMed - indexed for MEDLINE]
18.

Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.

Hombach AA, Abken H.

Immunotherapy. 2013 Jul;5(7):677-81. doi: 10.2217/imt.13.54. No abstract available.

PMID:
23829616
[PubMed - indexed for MEDLINE]
19.

Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy.

Ren-Heidenreich L, Lum LG.

Curr Gene Ther. 2001 Sep;1(3):253-5. Review.

PMID:
12109140
[PubMed - indexed for MEDLINE]
20.

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.

Ma Q, Gomes EM, Lo AS, Junghans RP.

Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.

PMID:
24174378
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk